Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Investor Presentation (October 2020)
27 slides from Cantargia Ab's investor presentation, October 2020
Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO October 2020
Slide 2: Safe Harbour Statement
Safe Harbour Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known an
Slide 3: Cantargia – Opportunity to save lives and create value
Cantargia – Opportunity to save lives and create value → Potentially more effective treatment against novel target in clinically validated pathway → Right team and clear plan to position our projects and maximize value → First in class platform technology against novel target 3
Slide 4: Cantargia at a glance
Cantargia at a glance Unique immunotherapy antibody CAN04 in phase IIa clinical development Current owners (30 June 2020) ▪ Positive interim data set with response rates higher than historic data ▪ Further phase II milestones during 2020 4th AP fund 7.8% Platform with many potential therapeutic area
Slide 5: Cantargia addresses a huge market
Cantargia addresses a huge market Incidence, Globally 2018 Mortality, Globally 2018 Type of cancer: Type of cancer: Lung: 22,6% Lung: 18,4% Lung cancer Pancreatic cancer Other: Other: 42,9% 35,8% Breast: Breast: 6,6% Incidence 2018 11,6% 2,093,876 458,918 Bowel: (globally) 9,2% Bowel: 10,2% Fraction
Slide 6: Lead antibody CAN04
=a (=) 2 <x (Ss) > mo} ° 2 r=) c © mo} is) ov ar
Slide 7: CAN04 – Mechanism of action
CAN04 – Mechanism of action 7 Note: ADCC = Antibody-Dependent Cellular Cytotoxicity. CAF = Cancer-Associated Fibroblast. NK = Natural Killer. MCP = Monocyte Chemoattractant Protein. MMP = Matrix Metallopeptidase. IL = Interleukin. VEGF = Vascular Endothelial Growth Factor
Slide 8: CAN04 – Dual anticancer mechanism
CAN04 – Dual anticancer mechanism NSCLC IL1a IL1b • Inhibition of IL-1 signaling: • ADCC enhanced antibody Ctrl CAN04 blocks tumor inflammation and stimulates direct killing of cancer cells 8
Slide 9: Validating study – Counteracting tumor inflammation
Validating study – Counteracting tumor inflammation CANTOS trial (n=10,061) Canakinumab phase III trials ▪ Canakinumab (Novartis) ▪ Reduced lung cancer incidence by 67% and death by 77% Adjuvant NSCLC ▪ 1,500 patients ▪ Reduced non-lung cancer death by 37% 3 (CANOPY-A) ▪ After surgery, no mets, plac
Slide 10: CAN04 – Superior MoA against other IL-1 blocking approaches
CAN04 – Superior MoA against other IL-1 blocking approaches Company Compound IL-1α IL-1β ADCC Indication/dev phase • Pancreatic cancer, NSCLC Cantargia CAN04 ++ ++ ++ phase IIa • Autoimmunity, Xbiotech/ Janssen Xilonix ++ – + dermatology • Pancreatic cancer, phase I • Autoimmunity, registered Canaki
Slide 11: Positive phase IIa interim combination data
Positive phase IIa interim combination data Initiated Evaluable CR/PR SD PD NE PDAC 10 7 41) 22) 12) → By adding CAN04 response rates are higher than historical data using these standard first line chemo- Historical 23% 27% 20% 30% therapies alone NSCLC 13 9 61) 3 → 4 of 7 evaluable patients with me
Slide 12: Tumor shrinkage in NSCLC combination
Tumor shrinkage in NSCLC combination Patient 1 2 3 4 5 6 7 8 9 → 6 of 9 evaluable patients with metastatic non-small cell 0 lung cancer (NSCLC) showed objective response including Percent tumor reduction 1 complete response (RECIST 1.1) PR → The complete response has lasted more than 1 year -50 → 5
Slide 13: CAN04 – CANFOUR clinical trial
CAN04 – CANFOUR clinical trial June PDAC NSCLC 2019 CANFOUR RESULTS Q4 Q1 2020 2020 Phase I – Dose escalation Phase IIa – Dosage with assessment with safety assessment of therapeutic effect Monotherapy Combination therapy, NSCLC (Dose group X) Recommended phase II dose Combination therapy, PDAC Dose
Slide 14: Targeting IL1RAP allows unique synergistic effects with chemotherapy (AACR 2020)
Targeting IL1RAP allows unique synergistic effects with chemotherapy (AACR 2020) → Upregulation of both forms of IL-1 in PDX-model treated with Gem/Cis → CAN04 increase efficacy of chemotherapy regimes → CAN04 counteract weight loss after chemotherapy Synergy with chemotherapy in line with current d
Slide 15: Chemotherapy resistance
Chemotherapy resistance → Most chemotherapies induce chemoresistance already after a few months of therapy → Chemotherapy upregulate both IL-1α and IL-1β → Blocking IL-1 signalling counteracts chemoresistance in preclinical models → High blood levels of inflammatory cytokines IL-1 and IL-6 leads to
Slide 16: Pancreatic cancer strategy
Pancreatic cancer strategy Subgroup Share (USA) Treatment Target Resectable 10% Surgery Cure Locally advanced 29% Chemotherapy Response, surgery Metastatic 52% Chemotherapy Response → USA: Estimate 57,000 cases 2019, 5 year survival rate Resectable 34%, Locally advanced 12%, Metastatic 3% → Preparat
Slide 17: CMC – Long term production strategy
CMC – Long term production strategy ▪ Transfer to Patheon (Groningen, NL) ▪ Processing method Technology transfer ▪ Equipment ▪ Analytical methods ▪ Assure GMP compliance Scale-up and first batch ▪ Product testing to confirm equivalence with at new production scale previous produced product ▪ Succes
Slide 18: CAN04 oncology expansion
c 2 7) c is) a x< oO > Los) 2 ° rs) c ° =a (=) 2 <x (Ss)
Slide 19: IL1RAP in several cancer with high medical need
IL1RAP in several cancer with high medical need IL1RAP Cantargia ▪ Discovery of IL1RAP on cancer cells founded ▪ Antibodies against IL1RAP – antitumor effects 120 based on ▪ IP on antibody therapy against IL1RAP 100 Primary ▪ Non-small cell lung cancer – NSCLC 80 indications ▪ Pancreatic cancer – PD
Slide 20: IL1RAP and PD-1 blockade – Rationale for combination study
IL1RAP and PD-1 blockade – Rationale for combination study ▪ Myeloid suppressive cells, such as tumor-associated macrophages (TAMs) or myeloid-derived suppressor cells (MDSCs) are key cells in PD-1 resistance and express IL1RAP and are stimulated by IL-1, these cells counteracts PD-1 blockade Chroni
Slide 21: US phase I clinical trial
US phase I clinical trial → First patient has started → Combination with checkpoint inhibitor in patients that no longer respond to PD1/PDL-1 therapy → Primary endpoint safety, secondary endpoints include biomarkers and efficacy → Indications include NSCLC, HNSCC, malignant melanoma and bladder canc
Slide 22: Untapped possibilities in autoimmune diseases
Untapped possibilities in autoimmune diseases
Slide 23: CAN10 – New development project
CAN10 – New development project → IL1RAP binding antibody potently blocking IL-1, IL-33 and IL-36 → Unique anti-inflammatory activity observed in mouse model → Development focusing on unmet medical need in systemic sclerosis and myocarditis. Disease selection in collaboration with experts based on s
Slide 24: CAN10 counteract inflammation in disease model
CAN10 counteract inflammation in disease model Total back score Isotype anti-IL-1β mCAN10 Dexamethasone 5 4 → Mechanistic proof of concept for IL1RAP blockade in Score (0-8) 3 inflammatory driven psoriasis model 2 → Effect not dependent on IL-1β blockade 1 0 0 1 2 3 4 5 6 7 Days CAN10 has unique ant
Slide 25: Milestones and summary
> re o S £ S yn me} c © i) oO c ie} _~ n a =
Slide 26: Significant value inflection points
Significant value inflection points Newsflow next 6-9 months CAN04 → LPI Phase IIa combination in PDAC → Phase IIa combination results PDAC and NSCLC → Next steps PDAC and NSCLC → Phase IIa biomarker/biopsy results → New clinical trial in disease/combination outside CANFOUR CAN10 → Preclinical progr
Slide 27: Cantargia at a glance
Cantargia at a glance Unique immunotherapy antibody CAN04 in phase IIa clinical development ▪ Positive interim data set and further phase II milestones during 2020 Platform with many potential therapeutic areas ▪ Cancer and large number of autoimmune/inflammatory diseases Vision of becoming an impor